408 related articles for article (PubMed ID: 26429955)
1. Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma.
Persson M; Nedergaard MK; Brandt-Larsen M; Skovgaard D; Jørgensen JT; Michaelsen SR; Madsen J; Lassen U; Poulsen HS; Kjaer A
J Nucl Med; 2016 Feb; 57(2):272-8. PubMed ID: 26429955
[TBL] [Abstract][Full Text] [Related]
2. Improved positron emission tomography imaging of glioblastoma cancer using novel
Loft MD; Sun Y; Liu C; Christensen C; Huang D; Kjaer A; Cheng Z
Amino Acids; 2017 Jun; 49(6):1089-1100. PubMed ID: 28316028
[TBL] [Abstract][Full Text] [Related]
3. First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts.
Persson M; Liu H; Madsen J; Cheng Z; Kjaer A
Nucl Med Biol; 2013 Jul; 40(5):618-24. PubMed ID: 23602763
[TBL] [Abstract][Full Text] [Related]
4. Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion.
Persson M; Madsen J; Østergaard S; Jensen MM; Jørgensen JT; Juhl K; Lehmann C; Ploug M; Kjaer A
J Nucl Med; 2012 Jan; 53(1):138-45. PubMed ID: 22213823
[TBL] [Abstract][Full Text] [Related]
5. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.
Persson M; Madsen J; Østergaard S; Ploug M; Kjaer A
Nucl Med Biol; 2012 May; 39(4):560-9. PubMed ID: 22172391
[TBL] [Abstract][Full Text] [Related]
6. Safety, Dosimetry, and Tumor Detection Ability of
Skovgaard D; Persson M; Brandt-Larsen M; Christensen C; Madsen J; Klausen TL; Holm S; Andersen FL; Loft A; Berthelsen AK; Pappot H; Brasso K; Kroman N; Højgaard L; Kjaer A
J Nucl Med; 2017 Mar; 58(3):379-386. PubMed ID: 27609788
[TBL] [Abstract][Full Text] [Related]
7. Urokinase-Type Plasminogen Activator Receptor (uPAR) Expression and [
Lawaetz M; Binderup T; Christensen A; Juhl K; Lelkaitis G; Lykke E; Knudsen L; von Buchwald C; Kjaer A
Mol Imaging Biol; 2023 Dec; 25(6):1034-1044. PubMed ID: 37749438
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Urokinase-Type Plasminogen Activator Receptor PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with
Risør LM; Clausen MM; Ujmajuridze Z; Farhadi M; Andersen KF; Loft A; Friborg J; Kjaer A
J Nucl Med; 2022 Aug; 63(8):1169-1176. PubMed ID: 34857658
[TBL] [Abstract][Full Text] [Related]
9. Dosimetry of 64Cu-DOTA-AE105, a PET tracer for uPAR imaging.
Persson M; El Ali HH; Binderup T; Pfeifer A; Madsen J; Rasmussen P; Kjaer A
Nucl Med Biol; 2014 Mar; 41(3):290-5. PubMed ID: 24533988
[TBL] [Abstract][Full Text] [Related]
10. Prospective Phase II Trial of Prognostication by
Carlsen EA; Loft M; Loft A; Berthelsen AK; Langer SW; Knigge U; Kjaer A
J Nucl Med; 2022 Sep; 63(9):1371-1377. PubMed ID: 35058319
[TBL] [Abstract][Full Text] [Related]
11. New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts.
Persson M; Rasmussen P; Madsen J; Ploug M; Kjaer A
Nucl Med Biol; 2012 Oct; 39(7):962-9. PubMed ID: 22739362
[TBL] [Abstract][Full Text] [Related]
12. In vivo detection of urokinase-type plasminogen activator receptor (uPAR) expression in arterial atherogenesis using [
Khare HA; Døssing KBV; Ringgaard L; Christensen E; Urbak L; Sillesen H; Ripa RS; Binderup T; Pedersen SF; Kjaer A
Atherosclerosis; 2022 Jul; 352():103-111. PubMed ID: 35396143
[TBL] [Abstract][Full Text] [Related]
13. Improved PET imaging of uPAR expression using new (64)Cu-labeled cross-bridged peptide ligands: comparative in vitro and in vivo studies.
Persson M; Hosseini M; Madsen J; Jørgensen TJ; Jensen KJ; Kjaer A; Ploug M
Theranostics; 2013; 3(9):618-32. PubMed ID: 24052804
[TBL] [Abstract][Full Text] [Related]
14. Imaging of urokinase-type plasminogen activator receptor expression using a 64Cu-labeled linear peptide antagonist by microPET.
Li ZB; Niu G; Wang H; He L; Yang L; Ploug M; Chen X
Clin Cancer Res; 2008 Aug; 14(15):4758-66. PubMed ID: 18676745
[TBL] [Abstract][Full Text] [Related]
15. Urokinase Plasminogen Activator Receptor-PET with
Skovgaard D; Persson M; Kjaer A
PET Clin; 2017 Jul; 12(3):311-319. PubMed ID: 28576169
[TBL] [Abstract][Full Text] [Related]
16. A novel urokinase plasminogen activator receptor-targeted peptide-based probe for in-vivo molecular imaging of glioblastoma.
Han Y; Tu L; Zhang Y; Xu L; Sun Z
Nucl Med Commun; 2023 Feb; 44(2):142-149. PubMed ID: 36630218
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive Detection of HER2 Expression in Gastric Cancer by
Guo X; Zhu H; Zhou N; Chen Z; Liu T; Liu F; Xu X; Jin H; Shen L; Gao J; Yang Z
Mol Pharm; 2018 Nov; 15(11):5174-5182. PubMed ID: 30251865
[TBL] [Abstract][Full Text] [Related]
18. PET imaging of insulin-like growth factor type 1 receptor expression with a 64Cu-labeled Affibody molecule.
Su X; Cheng K; Liu Y; Hu X; Meng S; Cheng Z
Amino Acids; 2015 Jul; 47(7):1409-19. PubMed ID: 25854877
[TBL] [Abstract][Full Text] [Related]
19. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
20. uPAR targeted radionuclide therapy with (177)Lu-DOTA-AE105 inhibits dissemination of metastatic prostate cancer.
Persson M; Juhl K; Rasmussen P; Brandt-Larsen M; Madsen J; Ploug M; Kjaer A
Mol Pharm; 2014 Aug; 11(8):2796-806. PubMed ID: 24955765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
